Do Wall Street Analysts Like Centene Stock?
Company Overview: Centene Corporation, a major healthcare provider in the U.S. with a market cap of $30.9 billion, focuses on government-sponsored programs and aims to improve health outcomes while facing challenges such as rising medical costs and profitability concerns.
Stock Performance and Analyst Ratings: Centene's stock has underperformed, dropping 18% over the past year, but analysts maintain a "Moderate Buy" consensus rating, with a price target suggesting potential upside, despite mixed earnings surprises in recent quarters.
Trade with 70% Backtested Accuracy
Analyst Views on XHS
About the author
Managed Care Stocks Show Mixed Performance in 2025: ALHC and OSCR Gain, While UNH and CNC Decline
Divergent Performance Among Insurers: In 2025, Alignment Healthcare stands out with an 81.4% year-to-date increase, while UnitedHealth Group faces significant challenges, down 35.13% YTD due to high medical costs and operational issues.
Impact of Policy Changes: The expiration of enhanced ACA subsidies on December 31, 2025, raises concerns about potential premium increases and coverage losses, with a Republican healthcare bill advancing that does not renew these subsidies.
Mixed Growth Expectations: CVS Health and Oscar Health show positive growth prospects, with CVS expected to have robust EPS growth through 2028, while Oscar Health continues its turnaround with a 10.1% gain.
Industry Uncertainty: The healthcare sector is experiencing pressure from rising utilization and federal funding cuts, leading to a cautious outlook for major insurers, particularly UnitedHealth, which anticipates a transition year in 2026.
Zacks Analyst Blog Features LLY, EPHE, BBC, HELX, XHS, and SURI
Market Overview: The stock market experienced a downturn last week, with the S&P 500, Dow Jones, and Nasdaq Composite all declining due to overvaluation concerns in the AI sector, despite NVIDIA's strong earnings report.
NVIDIA's Performance: NVIDIA reported a significant revenue increase of 62% year-over-year, driven by high demand for its AI data center chips, leading to an earnings per share of $1.30, surpassing expectations.
Eli Lilly's Milestone: Eli Lilly became the first healthcare company to reach a $1 trillion market cap, fueled by strong sales growth from its GLP-1/GIP drugs, Mounjaro and Zepbound, which contributed to a 36% stock surge this year.
Top-Performing ETFs: Several ETFs, including the iShares MSCI Philippines ETF and Virtus LifeSci Biotech Clinical Trials ETF, showed strong performance last week, reflecting investor interest in healthcare and biotech sectors amidst market volatility.
The Cigna Group Stock Outlook: Is Wall Street Bullish or Bearish?
Cigna Group Overview: Cigna Group, a major health services company with a market cap of $84.3 billion, has seen its stock decline by 13.5% over the past year, despite a 9.3% increase year-to-date. The company's performance has been affected by negative sentiment towards health insurers and government actions impacting its Evernorth division.
Analyst Ratings and Projections: Analysts maintain a consensus rating of "Strong Buy" for Cigna, with a mean price target suggesting a potential upside of 25.1% to 34.8%. The company is projected to achieve an 8.6% increase in non-GAAP earnings for the current fiscal year.
Cardinal Health Stock Outlook: Is Wall Street Bullish or Bearish?
Company Overview and Stock Performance: Cardinal Health, Inc. is a major healthcare services provider with a market cap of $35.5 billion, experiencing a 51.2% stock increase over the past year and a strong fiscal Q3 performance, raising its EPS guidance to $8.05–$8.16.
Analyst Ratings and Future Outlook: The consensus rating for CAH stock is a "Strong Buy," with Morgan Stanley raising its price target from $142 to $166, indicating potential upside, while analysts project a 7.8% earnings growth year-over-year for the current fiscal year.
DaVita Stock Outlook: Is Wall Street Bullish or Bearish?
Company Overview and Performance: DaVita Inc., a kidney dialysis service provider, has seen its stock underperform compared to the broader market, gaining only 5% over the past year while the S&P 500 rose nearly 11.9%. The company's recent ransomware attack has contributed to investor concerns, impacting operations.
Analyst Ratings and Future Projections: Analysts maintain a consensus "Hold" rating on DVA stock, with a price target of $169 suggesting a potential upside of 17%. Despite mixed earnings surprises, projections indicate an expected EPS growth of 11.2% for the current fiscal year.
How Is DaVita's Stock Performance Compared to Other Health Care Services Stocks?
Company Overview: DaVita Inc., a large-cap company valued at $12 billion, provides kidney dialysis services and holds over 35% market share in the U.S. dialysis market, known for its quality care and integrated healthcare approach.
Stock Performance and Challenges: Despite a 10.8% increase over the past year, DVA's stock has faced recent declines due to limited supply, rising patient care costs, and decreased patient volume, leading to cautious outlooks from analysts with a consensus "Hold" rating.
Managed Care Stocks Show Mixed Performance in 2025: ALHC and OSCR Gain, While UNH and CNC Decline
Divergent Performance Among Insurers: In 2025, Alignment Healthcare stands out with an 81.4% year-to-date increase, while UnitedHealth Group faces significant challenges, down 35.13% YTD due to high medical costs and operational issues.
Impact of Policy Changes: The expiration of enhanced ACA subsidies on December 31, 2025, raises concerns about potential premium increases and coverage losses, with a Republican healthcare bill advancing that does not renew these subsidies.
Mixed Growth Expectations: CVS Health and Oscar Health show positive growth prospects, with CVS expected to have robust EPS growth through 2028, while Oscar Health continues its turnaround with a 10.1% gain.
Industry Uncertainty: The healthcare sector is experiencing pressure from rising utilization and federal funding cuts, leading to a cautious outlook for major insurers, particularly UnitedHealth, which anticipates a transition year in 2026.
Zacks Analyst Blog Features LLY, EPHE, BBC, HELX, XHS, and SURI
Market Overview: The stock market experienced a downturn last week, with the S&P 500, Dow Jones, and Nasdaq Composite all declining due to overvaluation concerns in the AI sector, despite NVIDIA's strong earnings report.
NVIDIA's Performance: NVIDIA reported a significant revenue increase of 62% year-over-year, driven by high demand for its AI data center chips, leading to an earnings per share of $1.30, surpassing expectations.
Eli Lilly's Milestone: Eli Lilly became the first healthcare company to reach a $1 trillion market cap, fueled by strong sales growth from its GLP-1/GIP drugs, Mounjaro and Zepbound, which contributed to a 36% stock surge this year.
Top-Performing ETFs: Several ETFs, including the iShares MSCI Philippines ETF and Virtus LifeSci Biotech Clinical Trials ETF, showed strong performance last week, reflecting investor interest in healthcare and biotech sectors amidst market volatility.
The Cigna Group Stock Outlook: Is Wall Street Bullish or Bearish?
Cigna Group Overview: Cigna Group, a major health services company with a market cap of $84.3 billion, has seen its stock decline by 13.5% over the past year, despite a 9.3% increase year-to-date. The company's performance has been affected by negative sentiment towards health insurers and government actions impacting its Evernorth division.
Analyst Ratings and Projections: Analysts maintain a consensus rating of "Strong Buy" for Cigna, with a mean price target suggesting a potential upside of 25.1% to 34.8%. The company is projected to achieve an 8.6% increase in non-GAAP earnings for the current fiscal year.
Cardinal Health Stock Outlook: Is Wall Street Bullish or Bearish?
Company Overview and Stock Performance: Cardinal Health, Inc. is a major healthcare services provider with a market cap of $35.5 billion, experiencing a 51.2% stock increase over the past year and a strong fiscal Q3 performance, raising its EPS guidance to $8.05–$8.16.
Analyst Ratings and Future Outlook: The consensus rating for CAH stock is a "Strong Buy," with Morgan Stanley raising its price target from $142 to $166, indicating potential upside, while analysts project a 7.8% earnings growth year-over-year for the current fiscal year.
DaVita Stock Outlook: Is Wall Street Bullish or Bearish?
Company Overview and Performance: DaVita Inc., a kidney dialysis service provider, has seen its stock underperform compared to the broader market, gaining only 5% over the past year while the S&P 500 rose nearly 11.9%. The company's recent ransomware attack has contributed to investor concerns, impacting operations.
Analyst Ratings and Future Projections: Analysts maintain a consensus "Hold" rating on DVA stock, with a price target of $169 suggesting a potential upside of 17%. Despite mixed earnings surprises, projections indicate an expected EPS growth of 11.2% for the current fiscal year.
How Is DaVita's Stock Performance Compared to Other Health Care Services Stocks?
Company Overview: DaVita Inc., a large-cap company valued at $12 billion, provides kidney dialysis services and holds over 35% market share in the U.S. dialysis market, known for its quality care and integrated healthcare approach.
Stock Performance and Challenges: Despite a 10.8% increase over the past year, DVA's stock has faced recent declines due to limited supply, rising patient care costs, and decreased patient volume, leading to cautious outlooks from analysts with a consensus "Hold" rating.
